在癌症临床试验中,Hsp90抑制剂面临的以前未被认可和潜在的后果挑战
Cheng Chang1, Xin Tang1, David T Woodley1
1Department of Dermatology and USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Center, Los Angeles, CA 90033, USA.
Cell stress & chaperones
|August 24, 2024
概括
热冲击蛋白-90 (Hsp90) 抑制剂在癌症试验中由于器官特异性表达变异而失败. Hsp90α充当毒性缓冲剂,而Hsp90β驱动剂量限制性毒性,使得安全的最大可容忍剂量具有挑战性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 热冲击蛋白-90 (Hsp90) 伴侣抑制在癌症治疗中得到了广泛的研究,自1999年以来有200多项临床试验未能获得FDA批准.
- 以前的失败归因于Hsp90抑制剂,瘤或两者兼而有之,忽视了患者中Hsp90的显著器官间表达变异性.
研究的目的:
- 研究Hsp90表达异质性在不同器官中的作用,作为Hsp90向癌症治疗中缺乏成功的潜在原因.
- 阐明Hsp90α和Hsp90β异型在调解药物毒性和疗效方面的不同作用.
主要方法:
- 细胞和遗传研究的分析.
- 从人类蛋白质图谱数据库中检查Hsp90表达数据.
- 对Hsp90抑制剂的临床试验结果的审查.
主要成果:
- Hsp90β被确定为剂量限制性毒性 (DLT) 的主要驱动因素,而Hsp90α则起到缓冲作用,防止抑制剂诱导的毒性.
- 在各器官中存在Hsp90表达的显著变化 (例如,在眼睛中不存在,在肝脏中大量存在),这使得确定安全的最大可容忍剂量 (MTD) 变得复杂.
- 一些瘤细胞系不坚持预期的抑制剂结合-客户端蛋白质降解途径,像TAS-116这样的口服抑制剂通过向胃肠道瘤来显示有效性.
结论:
- 器官特定的Hsp90表达变异性是阻碍开发有效的癌症治疗Hsp90抑制剂的关键因素.
- 了解Hsp90α和Hsp90β的不同作用对于设计更安全,更有效的针对Hsp90的疗法至关重要.
- 未来的战略可能需要考虑有针对性的交付或专注于特定的Hsp90异型或表达模式,以克服毒性和疗效的挑战.
更多相关视频
07:57Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
5.2K
09:39Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
Published on: March 31, 2022
3.2K
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K